Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Keith_Gottesdiener
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
gene editing
prime editing |
| gptkbp:foundedYear |
2019
|
| gptkbp:founder |
gptkb:David_Liu
gptkb:Andrew_Anzalone |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prime Medicine
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:IPODate |
2022
|
| gptkbp:mission |
to deliver a new class of one-time curative genetic therapies
|
| gptkbp:notableInvestment |
gptkb:Andreessen_Horowitz
gptkb:Arch_Venture_Partners gptkb:Casdin_Capital gptkb:F-Prime_Capital gptkb:GV_(Google_Ventures) |
| gptkbp:notablePerson |
gptkb:David_Liu
gptkb:Andrew_Anzalone |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
genetic diseases
therapeutic genome editing |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:PRME
|
| gptkbp:technology |
prime editing
|
| gptkbp:website |
https://primemedicine.com/
|
| gptkbp:bfsParent |
gptkb:David_R._Liu
|
| gptkbp:bfsLayer |
4
|